

Raiffeisen Health and Wellbeing ESG Equities

(Original German name: Raiffeisen-Health and Wellbeing-ESG-Aktien)

semi-annual fund report

reporting period Jun 1, 2024 – Nov 30, 2024

Table of contents

| | |
|--|----|
| General fund information..... | 3 |
| Fund characteristics | 3 |
| Legal notice..... | 4 |
| Fund details..... | 5 |
| Units in circulation | 5 |
| Makeup of fund assets in EUR | 6 |
| Portfolio of investments in EUR as of Nov 29, 2024 | 7 |
| Appendix..... | 12 |

Report for the reporting period from Jun 1, 2024 to Nov 30, 2024

General fund information

| ISIN | Tranche | Income class | Currency | Launch date |
|--------------|--|--|----------|--------------|
| AT0000714274 | Raiffeisen Health and Wellbeing ESG Equities (R) A | income-distributing | EUR | Apr 18, 2001 |
| AT0000A1U651 | Raiffeisen Health and Wellbeing ESG Equities (RZ) A | income-distributing | EUR | Apr 3, 2017 |
| AT0000714282 | Raiffeisen Health and Wellbeing ESG Equities (R) T | income-retaining | EUR | Apr 18, 2001 |
| AT0000A1U644 | Raiffeisen Health and Wellbeing ESG Equities (RZ) T | income-retaining | EUR | Apr 3, 2017 |
| AT0000A2XN33 | Raiffeisen Health and Wellbeing ESG Equities (SZ) T ¹ | income-retaining | EUR | Jun 1, 2022 |
| AT0000712716 | Raiffeisen Health and Wellbeing ESG Equities (R) VTA | full income-retaining (outside Austria) | EUR | Oct 29, 2002 |

¹ Tranche SZ is exclusively for investments within the scope of the Raiffeisen Banking Group's sustainable asset management.

Fund characteristics

| | |
|--|---|
| Fund currency | EUR |
| Financial year | Jun 1 – May 31 |
| Distribution/payment/reinvestment date | Aug 16 |
| Type of fund | Investment fund pursuant to § 2 of the Austrian Investment Fund Act, InvFG (UCITS) |
| Effective management fee for the fund | R-Tranche (EUR): 2.000 % RZ-Tranche (EUR): 1.000 % SZ-Tranche (EUR): 0.650 % |
| Custodian bank | Raiffeisen Bank International AG |
| Management company | Raiffeisen Kapitalanlage-Gesellschaft m.b.H. Mooslackengasse 12, A-1190 Vienna Tel. +43 1 71170-0 Fax +43 1 71170-761092 www.rcm.at Companies register number: 83517 w |
| Fund management | Raiffeisen Kapitalanlage-Gesellschaft m.b.H. |
| Auditor | KPMG Austria GmbH |

The fund is actively managed without reference to a benchmark.

Legal notice

The software used performs calculations on the basis of more than the two decimal places displayed. Minor discrepancies cannot be ruled out due to further calculations using published results.

The value of a unit is calculated by dividing the entire value of the investment fund inclusive of its income by the number of units. The total value of the investment fund is calculated on the basis of the current market prices of the securities, money market instruments and subscription rights in the fund plus the value of the fund's financial investments, cash holdings, credit balances, receivables and other rights net of its payables. That value will be calculated by the custodian bank.

The net assets are calculated in accordance with the following principles:

- a) The value of assets quoted or traded on a stock exchange or other regulated market shall be determined, in principle, on the basis of the most recently available price.
- b) Where an asset is not quoted or traded on a stock market or another regulated market or where the price for an asset quoted or traded on a stock market or another regulated market does not appropriately reflect its actual market value, the prices provided by reliable data providers or, alternatively, market prices for equivalent securities or other recognized market valuation methods shall be used.

The performance is calculated by Raiffeisen KAG on the basis of published fund prices, using the method developed by OeKB (Österreichische Kontrollbank AG). Individual costs such as transaction fees, the subscription fee, the redemption fee, the custody charges of the investor and taxes are not included in the performance calculation. If included, these would lead to a lower performance. Past performance is not a reliable indicator of future performance. Markets could develop very differently in the future. Based on the illustration, you can assess how the fund was managed in the past.

Dear unitholder,

Raiffeisen Kapitalanlage-Gesellschaft m.b.H. is pleased to present its semi-annual fund report for Raiffeisen Health and Wellbeing ESG Equities for the reporting period from Jun 1, 2024 to Nov 30, 2024. The accounting is based on the price calculation as of Nov 29, 2024.

Fund details

| | May 31, 2024 | Nov 30, 2024 |
|--|----------------|----------------|
| Total fund assets in EUR | 224,682,682.48 | 235,125,894.44 |
| Net asset value/distributing units (R) (AT0000714274) in EUR | 251.73 | 256.70 |
| Issue price/distributing units (R) (AT0000714274) in EUR | 251.73 | 256.70 |
| Net asset value/distributing units (RZ) (AT0000A1U651) in EUR | 154.07 | 157.91 |
| Issue price/distributing units (RZ) (AT0000A1U651) in EUR | 154.07 | 157.91 |
| Net asset value/reinvested units (R) (AT0000714282) in EUR | 312.06 | 322.20 |
| Issue price/reinvested units (R) (AT0000714282) in EUR | 312.06 | 322.20 |
| Net asset value/reinvested units (RZ) (AT0000A1U644) in EUR | 167.21 | 172.99 |
| Issue price/reinvested units (RZ) (AT0000A1U644) in EUR | 167.21 | 172.99 |
| Net asset value/reinvested units (SZ) (AT0000A2XN33) in EUR | 112.38 | 116.38 |
| Issue price/reinvested units (SZ) (AT0000A2XN33) in EUR | 112.38 | 116.38 |
| Net asset value/fully reinvested units (I) (AT0000A2R8Q2) in EUR | 123.66 | - ¹ |
| Issue price/fully reinvested units (I) (AT0000A2R8Q2) in EUR | 123.66 | - ¹ |
| Net asset value/fully reinvested units (R) (AT0000712716) in EUR | 329.83 | 340.89 |
| Issue price/fully reinvested units (R) (AT0000712716) in EUR | 329.83 | 340.89 |

Units in circulation

| | Units in circulation on May 31, 2024 | Sales | Repurchases | Units in circulation on Nov 30, 2024 |
|-----------------------------------|---|------------|-------------|---|
| AT0000714274 (R) A | 59,933.975 | 2,183.242 | -3,397.194 | 58,720.023 |
| AT0000A1U651 (RZ) A | 39,646.929 | 1,451.675 | -1,061.617 | 40,036.987 |
| AT0000714282 (R) T | 350,389.767 | 29,912.685 | -27,496.924 | 352,805.528 |
| AT0000A1U644 (RZ) T | 237,691.153 | 19,343.467 | -10,221.025 | 246,813.595 |
| AT0000A2XN33 (SZ) T | 10.000 | 0.000 | 0.000 | 10.000 |
| AT0000A2R8Q2 (I) VTA | 10.000 | 0.000 | -10.000 | - ¹ |
| AT0000712716 (R) VTA | 164,921.481 | 20,958.963 | -17,632.982 | 168,247.462 |
| Total units in circulation | | | | 866,633.595 |

¹ As of September 30, 2024, the fully accumulating I tranche was dissolved.

Makeup of fund assets in EUR

Any discrepancies in terms of the market value or the share of the fund assets result from rounding-off.

UCITS refers to units in an undertaking for collective investment in transferable securities

§ 166 InvFG refers to units in investment funds in the form of "other portfolios of assets"

§ 166 (1) item 2 InvFG refers to units in special funds

§ 166 (1) item 3 InvFG refers to units in undertakings for collective investment in transferable securities pursuant to § 166 (1) item 3 InvFG (such as alternative investments/hedge funds)

§ 166 (1) item 4 InvFG refers to units in real estate funds

| Type of security | OGAW/§ 166 | Currency | Market value in EUR | Share of fund assets |
|---|------------|----------|-----------------------|----------------------|
| Equities | | AUD | 2,810,174.29 | 1.20 % |
| Equities | | CHF | 12,745,372.61 | 5.42 % |
| Equities | | DKK | 12,928,168.20 | 5.50 % |
| Equities | | EUR | 18,038,420.00 | 7.67 % |
| Equities | | GBP | 12,873,963.47 | 5.48 % |
| Equities | | JPY | 6,044,782.77 | 2.57 % |
| Equities | | NOK | 1,034,544.85 | 0.44 % |
| Equities | | SEK | 6,463,855.52 | 2.75 % |
| Equities | | USD | 159,587,341.99 | 67.87 % |
| Total Equities | | | 232,526,623.70 | 98.89 % |
| Equities ADR | | USD | 1,143,885.91 | 0.49 % |
| Total Equities ADR | | | 1,143,885.91 | 0.49 % |
| Total securities | | | 233,670,509.61 | 99.38 % |
| Bank balances/liabilities | | | | |
| Bank balances/liabilities in fund currency | | | 1,698,191.77 | 0.72 % |
| Total bank balances/liabilities | | | 1,698,191.77 | 0.72 % |
| Accruals and deferrals | | | | |
| Interest claims (on securities and bank balances) | | | 4,718.54 | 0.00 % |
| Dividends receivable | | | 177,224.88 | 0.08 % |
| Total accruals and deferrals | | | 181,943.42 | 0.08 % |
| Other items | | | | |
| Various fees | | | -424,750.36 | -0.18 % |
| Total other items | | | -424,750.36 | -0.18 % |
| Total fund assets | | | 235,125,894.44 | 100.00 % |

Portfolio of investments in EUR as of Nov 29, 2024

Dates indicated for securities refer to the issue and redemption dates. An issuer's right of premature redemption (where applicable) is not specified.

The securities marked with a "Y" have an open-ended maturity (is perpetual). The price for forward exchange transactions is indicated in the relevant counter currency for the currency in question.

Any discrepancies in terms of the market value or the share of the fund assets result from rounding-off.

UCITS refers to units in an undertaking for collective investment in transferable securities

§ 166 InvFG refers to units in investment funds in the form of "other portfolios of assets"

§ 166 (1) item 2 InvFG refers to units in special funds

§ 166 (1) item 3 InvFG refers to units in undertakings for collective investment in transferable securities pursuant to § 166 (1) item 3 InvFG (such as alternative investments/hedge funds)

§ 166 (1) item 4 InvFG refers to units in real estate funds

| Type of security | OGAW/§ 166 | ISIN | Security title | Currency | Volume Units/Nom. | Purchases In period under review Units/Nom. | Sales Units/Nom. | Pool-/ ILB Factor | Price | Market value in EUR | Share of fund assets |
|------------------|------------|--------------|-----------------------------------|----------|----------------------|---|---------------------|----------------------|--------------|------------------------|-------------------------|
| Equities | | AU000000CSL8 | CSL LTD CSL | AUD | 16,000 | | | | 285.180000 | 2,810,174.29 | 1.20 % |
| Equities | | CH0432492467 | ALCON INC ALC | CHF | 27,000 | | 4,000 | | 78.040000 | 2,260,936.75 | 0.96 % |
| Equities | | CH0030170408 | GEBERIT AG-REG GEBN | CHF | 1,800 | | 500 | | 525.200000 | 1,014,389.18 | 0.43 % |
| Equities | | CH0013841017 | LONZA GROUP AG-REG LONN | CHF | 3,000 | | 2,000 | | 520.400000 | 1,675,197.17 | 0.71 % |
| Equities | | CH0012005267 | NOVARTIS AG-REG NOVN | CHF | 40,000 | | | | 93.380000 | 4,007,940.34 | 1.70 % |
| Equities | | CH0012032048 | ROCHE HOLDING AG-GENUSSCHEIN ROG | CHF | 13,900 | | 3,100 | | 253.900000 | 3,786,909.17 | 1.61 % |
| Equities | | DK0061802139 | ALK-ABELLO A/S ALKB | DKK | 70,000 | 10,000 | 30,000 | | 158.700000 | 1,489,601.35 | 0.63 % |
| Equities | | DK0010272202 | GENMAB A/S GMAB | DKK | 5,000 | | | | 1,511.000000 | 1,013,046.92 | 0.43 % |
| Equities | | DK0062498333 | NOVO NORDISK A/S-B NOVOB | DKK | 104,000 | 3,000 | 6,000 | | 747.600000 | 10,425,519.93 | 4.43 % |
| Equities | | NL0011872650 | BASIC-FIT NV BFIT | EUR | 50,000 | | | | 21.600000 | 1,080,000.00 | 0.46 % |
| Equities | | FR0006174348 | BUREAU VERITAS SA BVI | EUR | 36,000 | | 14,000 | | 28.580000 | 1,028,880.00 | 0.44 % |
| Equities | | FR0000121667 | ESSILORLUXOTTICA EL | EUR | 10,000 | | | | 228.500000 | 2,285,000.00 | 0.97 % |
| Equities | | DE0005664809 | EVOTEC SE EVT | EUR | 235,000 | 13,000 | | | 9.050000 | 2,126,750.00 | 0.90 % |
| Equities | | DE000A0LD6E6 | GERRESHEIMER AG GXI | EUR | 20,000 | 3,000 | | | 74.100000 | 1,482,000.00 | 0.63 % |
| Equities | | IE0000669501 | GLANBIA PLC GLB | EUR | 45,000 | 45,000 | | | 14.600000 | 657,000.00 | 0.28 % |
| Equities | | ES0171996095 | GRIFOLS SA - B GRF/P | EUR | 400,000 | | | | 6.430000 | 2,572,000.00 | 1.09 % |
| Equities | | DE0006599905 | MERCK KGAA MRK | EUR | 4,200 | | 800 | | 140.950000 | 591,990.00 | 0.25 % |
| Equities | | FR0000120578 | SANOFI SAN | EUR | 40,000 | 2,000 | 2,000 | | 92.100000 | 3,684,000.00 | 1.57 % |
| Equities | | IT0005162406 | TECHNOGYM SPA TGYM | EUR | 120,000 | | 30,000 | | 10.390000 | 1,246,800.00 | 0.53 % |
| Equities | | FR0000031577 | VIRBAC SA VIRP | EUR | 4,000 | 400 | 1,000 | | 321.000000 | 1,284,000.00 | 0.55 % |
| Equities | | GB0009895292 | ASTRAZENECA PLC AZN | GBP | 55,000 | 2,000 | 4,000 | | 105.940000 | 7,002,403.56 | 2.98 % |
| Equities | | GB00BN7SWP63 | GSK PLC GSK | GBP | 210,000 | 40,000 | | | 13.405000 | 3,383,066.94 | 1.44 % |
| Equities | | GB00BP92CJ43 | TATE & LYLE PLC TATE | GBP | 135,000 | 20,000 | 25,000 | | 7.390000 | 1,198,954.45 | 0.51 % |
| Equities | | GB00B39J2M42 | UNITED UTILITIES GROUP PLC UU/ | GBP | 95,000 | | 5,000 | | 11.295000 | 1,289,538.52 | 0.55 % |
| Equities | | JP3942400007 | ASTELLAS PHARMA INC 4503 | JPY | 110,000 | | | | 1,571.500000 | 1,081,001.14 | 0.46 % |
| Equities | | JP3475350009 | DAIICHI SANKYO CO LTD 4568 | JPY | 100,000 | 10,000 | 3,000 | | 4,717.000000 | 2,949,748.28 | 1.25 % |
| Equities | | JP3266400005 | KUBOTA CORP 6326 | JPY | 72,000 | | | | 1,914.500000 | 861,999.37 | 0.37 % |
| Equities | | JP3270000007 | KURITA WATER INDUSTRIES LTD 6370 | JPY | 32,000 | | 3,000 | | 5,757.000000 | 1,152,033.98 | 0.49 % |
| Equities | | NO0003054108 | MOWI ASA MOWI | NOK | 60,000 | 60,000 | | | 201.100000 | 1,034,544.85 | 0.44 % |
| Equities | | SE0021309614 | AUTOLIV INC-SWED DEP RECEIPT ALIV | SEK | 11,000 | | | | 1,089.400000 | 1,039,188.31 | 0.44 % |
| Equities | | SE0009922164 | ESSITY AKTIEBOLAG-B ESSITYB | SEK | 44,000 | | 16,000 | | 304.000000 | 1,159,953.17 | 0.49 % |
| Equities | | SE0000202624 | GETINGE AB-B SHS GETIB | SEK | 75,000 | | | | 171.250000 | 1,113,796.99 | 0.47 % |
| Equities | | SE0000872095 | SWEDISH ORPHAN BIOVITRUM AB SOBI | SEK | 56,000 | 6,000 | 10,000 | | 305.800000 | 1,485,045.31 | 0.63 % |
| Equities | | SE0011205202 | VITROLIFE AB VITR | SEK | 85,000 | 20,000 | 25,000 | | 226.000000 | 1,665,871.74 | 0.71 % |
| Equities | | US0028241000 | ABBOTT LABORATORIES ABT | USD | 59,000 | 3,000 | 6,000 | | 118.950000 | 6,649,973.94 | 2.83 % |

reporting period Jun 1, 2024 – Nov 30, 2024

Raiffeisen Health and Wellbeing ESG Equities

| Type of security | OGAW/§ 166 | ISIN | Security title | Currency | Volume Units/Nom. | Purchases In period under review Units/Nom. | Sales Units/Nom. | Pool-/ ILB Factor | Price | Market value in EUR | Share of fund assets |
|------------------|------------|--------------|-----------------------------------|----------|-------------------|---|------------------|-------------------|------------|---------------------|----------------------|
| Equities | | US00287Y1091 | ABBVIE INC ABBV | USD | 58,042 | | 500 | | 183.080000 | 10,069,009.67 | 4.28 % |
| Equities | | US00404A1097 | ACADIA HEALTHCARE CO INC ACHC | USD | 40,000 | 5,000 | 5,000 | | 41.280000 | 1,564,599.42 | 0.67 % |
| Equities | | US00846U1016 | AGILENT TECHNOLOGIES INC A | USD | 10,000 | | 4,000 | | 138.140000 | 1,308,949.64 | 0.56 % |
| Equities | | US0197701065 | ALLOGENE THERAPEUTICS INC ALLO | USD | 430,000 | 600,000 | 170,000 | | 2.500000 | 1,018,619.42 | 0.43 % |
| Equities | | US0304201033 | AMERICAN WATER WORKS CO INC AWK | USD | 9,000 | | 1,400 | | 138.310000 | 1,179,504.43 | 0.50 % |
| Equities | | US0311621009 | AMGEN INC AMGN | USD | 19,000 | | | | 280.070000 | 5,042,241.91 | 2.14 % |
| Equities | | US07373V1052 | BEAM THERAPEUTICS INC BEAM | USD | 50,000 | 50,000 | | | 27.200000 | 1,288,672.00 | 0.55 % |
| Equities | | US0758871091 | BECTON DICKINSON AND CO BDX | USD | 3,000 | | 6,000 | | 221.980000 | 631,013.41 | 0.27 % |
| Equities | | US09061G1013 | BIOMARIN PHARMACEUTICAL INC BMRN | USD | 13,000 | | 3,000 | | 65.420000 | 805,855.88 | 0.34 % |
| Equities | | US1011371077 | BOSTON SCIENTIFIC CORP BSX | USD | 68,000 | 7,000 | 9,000 | | 90.750000 | 5,847,349.22 | 2.49 % |
| Equities | | US1101221083 | BRISTOL-MYERS SQUIBB CO BMY | USD | 95,000 | 10,000 | 5,000 | | 59.270000 | 5,335,338.99 | 2.27 % |
| Equities | | US12674W1099 | CABALETTA BIO INC CABA | USD | 220,000 | 220,000 | | | 3.010000 | 627,469.56 | 0.27 % |
| Equities | | US03073E1055 | CENCORA INC COR | USD | 8,000 | 2,000 | | | 249.690000 | 1,892,755.96 | 0.80 % |
| Equities | | US2166485019 | COOPER COS INC/THE COO | USD | 15,000 | 3,000 | 1,500 | | 103.430000 | 1,470,081.02 | 0.63 % |
| Equities | | US2358511028 | DANAHER CORP DHR | USD | 23,000 | 2,000 | 4,000 | | 238.830000 | 5,204,993.60 | 2.21 % |
| Equities | | US2521311074 | DEXCOM INC DXCM | USD | 18,000 | | 2,000 | | 78.100000 | 1,332,069.93 | 0.57 % |
| Equities | | US28176E1082 | EDWARDS LIFESCIENCES CORP EW | USD | 30,000 | 12,500 | 10,000 | | 72.070000 | 2,048,704.22 | 0.87 % |
| Equities | | US5324571083 | ELI LILLY & CO LLY | USD | 27,600 | 1,000 | 600 | | 788.190000 | 20,613,108.45 | 8.77 % |
| Equities | | US30050B1017 | EVOLENT HEALTH INC - A EVH | USD | 90,000 | 90,000 | | | 12.930000 | 1,102,667.36 | 0.47 % |
| Equities | | US3755581036 | GILEAD SCIENCES INC GILD | USD | 41,000 | | 4,000 | | 92.410000 | 3,590,098.07 | 1.53 % |
| Equities | | US4052171000 | HAIN CELESTIAL GROUP INC HAIN | USD | 120,000 | | | | 8.630000 | 981,285.83 | 0.42 % |
| Equities | | US40412C1018 | HCA HEALTHCARE INC HCA | USD | 2,200 | 2,200 | | | 325.470000 | 678,480.13 | 0.29 % |
| Equities | | US4448591028 | HUMANA INC HUM | USD | 6,000 | 2,000 | | | 296.680000 | 1,686,720.05 | 0.72 % |
| Equities | | IE0005711209 | ICON PLC ICLR | USD | 5,000 | 5,000 | | | 212.840000 | 1,008,385.84 | 0.43 % |
| Equities | | US45168D1046 | IDEXX LABORATORIES INC IDXX | USD | 3,500 | | 1,500 | | 421.760000 | 1,398,739.75 | 0.59 % |
| Equities | | US46116X1019 | INTRA-CELLULAR THERAPIES INC ITCI | USD | 17,000 | 2,000 | 7,000 | | 86.590000 | 1,394,826.36 | 0.59 % |
| Equities | | US46120E6023 | INTUITIVE SURGICAL INC ISRG | USD | 15,000 | 1,500 | 3,500 | | 538.550000 | 7,654,569.57 | 3.26 % |
| Equities | | US4622601007 | IOVANCE BIOTHERAPEUTICS INC IOVA | USD | 100,000 | 50,000 | 20,000 | | 9.400000 | 890,699.77 | 0.38 % |
| Equities | | US46266C1053 | IQVIA HOLDINGS INC IQV | USD | 6,000 | | | | 201.430000 | 1,145,193.54 | 0.49 % |
| Equities | | IE00B4Q5ZN47 | JAZZ PHARMACEUTICALS PLC JAZZ | USD | 8,000 | 1,000 | 3,000 | | 122.640000 | 929,663.14 | 0.40 % |
| Equities | | US5500211090 | LULULEMON ATHLETICA INC LULU | USD | 3,300 | | | | 319.520000 | 999,114.99 | 0.42 % |
| Equities | | US58155Q1031 | MCKESSON CORP MCK | USD | 7,000 | 7,000 | | | 626.380000 | 4,154,697.49 | 1.77 % |
| Equities | | US58933Y1055 | MERCK & CO. INC. MRK | USD | 84,600 | | 3,400 | | 103.120000 | 8,266,406.41 | 3.52 % |
| Equities | | US5534981064 | MSA SAFETY INC MSA | USD | 6,000 | | 2,000 | | 174.320000 | 991,064.58 | 0.42 % |
| Equities | | US64125C1099 | NEUROCRINE BIOSCIENCES INC NBIX | USD | 11,000 | | 1,000 | | 126.590000 | 1,319,458.00 | 0.56 % |
| Equities | | US75629V1044 | RECURSION PHARMACEUTICALS-A RXRX | USD | 150,000 | 30,000 | | | 6.380000 | 906,808.17 | 0.39 % |
| Equities | | US75943R1023 | RELAY THERAPEUTICS INC RLY | USD | 180,000 | 10,000 | | | 4.800000 | 818,685.74 | 0.35 % |
| Equities | | GB00BMVP7Y09 | ROYALTY PHARMA PLC- CL A RPRX | USD | 20,000 | | 20,000 | | 26.600000 | 504,098.17 | 0.21 % |
| Equities | | IE00BFY8C754 | STERIS PLC STE | USD | 5,000 | | | | 217.470000 | 1,030,321.69 | 0.44 % |
| Equities | | US8636671013 | STRYKER CORP SYK | USD | 15,500 | 2,500 | | | 388.140000 | 5,700,639.60 | 2.42 % |
| Equities | | CA8676EP1086 | SUNOPTA INC STKL | USD | 155,000 | 10,000 | 35,000 | | 7.810000 | 1,147,060.22 | 0.49 % |
| Equities | | US1255231003 | THE CIGNA GROUP CI | USD | 10,000 | | 2,000 | | 336.500000 | 3,188,515.66 | 1.36 % |
| Equities | | US8835561023 | THERMO FISHER SCIENTIFIC INC TMO | USD | 12,500 | 2,000 | 2,500 | | 521.660000 | 6,178,755.86 | 2.63 % |
| Equities | | US91324P1021 | UNITEDHEALTH GROUP INC UNH | USD | 29,700 | 3,700 | | | 608.380000 | 17,121,226.13 | 7.28 % |
| Equities | | US92532F1003 | VERTEX PHARMACEUTICALS INC VRTX | USD | 13,000 | 2,000 | 1,000 | | 464.560000 | 5,722,537.55 | 2.43 % |
| Equities | | US92847W1036 | VITAL FARMS INC VITL | USD | 24,000 | | 1,000 | | 32.340000 | 735,452.69 | 0.31 % |

| Type of security | OGAW/§ 166 | ISIN | Security title | Currency | Volume Units/Nom. | Purchases In period under review Units/Nom. | Sales Units/Nom. | Pool-/ ILB Factor | Price | Market value in EUR | Share of fund assets |
|---|------------|--------------|--------------------------------|----------|----------------------|---|---------------------|----------------------|------------|------------------------|-------------------------|
| Equities | | US98956P1021 | ZIMMER BIOMET HOLDINGS INC ZBH | USD | 10,000 | | 4,000 | | 112.020000 | 1,061,448.81 | 0.45 % |
| Equities | | US98978V1035 | ZOETIS INC ZTS | USD | 20,000 | | 2,000 | | 176.740000 | 3,349,410.15 | 1.42 % |
| Equities ADR | | US09075V1026 | BIONTECH SE-ADR BNTX | USD | 10,000 | | | | 120.720000 | 1,143,885.91 | 0.49 % |
| Total licensed securities admitted to trading on the official market or another regulated market | | | | | | | | | | 233,670,509.61 | 99.38 % |
| Total securities | | | | | | | | | | 233,670,509.61 | 99.38 % |
| Bank balances/liabilities | | | | | | | | | | | |
| | | | | EUR | | | | | | 1,698,191.77 | 0.72 % |
| Total bank balances/liabilities | | | | | | | | | | 1,698,191.77 | 0.72 % |
| Accruals and deferrals | | | | | | | | | | | |
| Interest claims (on securities and bank balances) | | | | | | | | | | 4,718.54 | 0.00 % |
| Dividends receivable | | | | | | | | | | 177,224.88 | 0.08 % |
| Total accruals and deferrals | | | | | | | | | | 181,943.42 | 0.08 % |
| Other items | | | | | | | | | | | |
| Various fees | | | | | | | | | | -424,750.36 | -0.18 % |
| Total other items | | | | | | | | | | -424,750.36 | -0.18 % |
| Total fund assets | | | | | | | | | | 235,125,894.44 | 100.00 % |

| ISIN | Income class | | Currency | Net asset value per unit | Units in circulation |
|--------------|--------------|---|----------|--------------------------|----------------------|
| AT0000714274 | R | income-distributing | EUR | 256.70 | 58,720.023 |
| AT0000A1U651 | RZ | income-distributing | EUR | 157.91 | 40,036.987 |
| AT0000714282 | R | income-retaining | EUR | 322.20 | 352,805.528 |
| AT0000A1U644 | RZ | income-retaining | EUR | 172.99 | 246,813.595 |
| AT0000A2XN33 | SZ | income-retaining | EUR | 116.38 | 10.000 |
| AT0000712716 | R | full income-retaining (outside Austria) | EUR | 340.89 | 168,247.462 |

Exchange rates

Foreign currency assets were converted into EUR on the basis of the exchange rates applicable on Nov 28, 2024

| Currency | | Price (1 EUR =) |
|--------------------|-----|-----------------|
| Australian Dollars | AUD | 1.623700 |
| Swiss Francs | CHF | 0.931950 |
| Danish Kroner | DKK | 7.457700 |
| British Pound | GBP | 0.832100 |
| Japanese Yen | JPY | 159.911950 |
| Norwegian Kroner | NOK | 11.663100 |
| Swedish Krona | SEK | 11.531500 |
| US Dollars | USD | 1.055350 |

Securities purchases and sales during the period under review not listed under the portfolio of assets:

| Type of security | OGAW/§ 166 | ISIN | Security title | Currency | | Purchases Additions | Sales Disposals |
|---------------------|------------|--------------|------------------------------------|----------|--|------------------------|--------------------|
| Equities | | US1488061029 | CATALENT INC CTLT | USD | | | 40,000 |
| Subscription rights | | FR001400OP17 | ESSILORLUXOTTICA SA-SCRIP 2445084D | EUR | | | 10,000 |

Information on securities lending transactions and repurchase agreements

During the reporting period, no securities lending transactions were performed on behalf of the fund. Accordingly, the information concerning securities lending transactions which is stipulated in § 8 of the Austrian Securities Lending and Repurchase Agreement Ordinance and Art. 13 of Regulation (EU) No. 2015/2365 is not required.

During the reporting period, no repurchase agreements were concluded on behalf of the fund. Accordingly, the information concerning repurchase agreements which is stipulated in § 8 of the Austrian Securities Lending and Repurchase Agreement Ordinance and Art. 13 of Regulation (EU) No. 2015/2365 is not required.

Total return swaps and similar derivative instruments



A total return swap is a credit derivative instrument. Income and fluctuations in the value of the underlying financial instrument (underlying instrument or reference asset) are exchanged for fixed interest payments.

The fund did not enter into total return swaps or similar derivative instruments in the period under review.

Raiffeisen Kapitalanlage-Gesellschaft m.b.H. complies with the code of conduct for the Austrian investment fund industry 2012.

Vienna, 27 January 2025

Raiffeisen Kapitalanlage-Gesellschaft m.b.H.


Mag. (FH) Dieter Aigner
Ing. Michal Kuštra
Mag. Hannes Cizek

Appendix

Imprint

Publisher:

Raiffeisen Kapitalanlage-Gesellschaft m.b.H.
Mooslackengasse 12, A-1190 Vienna

Responsible for contents:

Raiffeisen Kapitalanlage-Gesellschaft m.b.H.
Mooslackengasse 12, A-1190 Vienna

Copyright by publisher, dispatch location: Vienna

Raiffeisen Capital Management is the brand of:
Raiffeisen Kapitalanlage-Gesellschaft m.b.H.
Raiffeisen Immobilien Kapitalanlage-Gesellschaft m.b.H.